Recognizing and treating Mycobacterium avium complex pulmonary disease (MAC-PD)

Mycobacterium avium complex pulmonary disease (MAC-PD) is an increasingly recognized cause of chronic pulmonary infection, yet it remains frequently missed in clinical practice due to its nonspecific presentation and overlap with more common conditions. This clinical review summarizes the pathogenesis, risk factors, clinical presentation, diagnostic criteria, differential diagnosis, pharmacologic treatment, and supportive care of MAC-PD for advanced practice clinicians. Two clinical phenotypes are discussed: fibrocavitary disease, seen more often in older men with structural lung disease, and nodular bronchiectatic disease, seen more often in older women. Diagnosis requires meeting clinical, radiographic, and microbiologic criteria per the 2020 ATS/ERS/ESCMID/IDSA guideline. Treatment consists of a macrolide-based three-drug regimen guided by disease phenotype, severity, and drug susceptibility that is continued for at least 12 months after sputum culture conversion. Airway clearance therapy, nutritional support, and mitigation of environmental and other modifiable risk factors are integral to comprehensive management. Recognizing MAC-PD early and initiating appropriate treatment can prevent progressive lung damage and improve quality of life for affected patients.

Authors

Publication Details

Journal
JAAPA
Published
2026-11-19
DOI
https://doi.org/10.1097/01.jaa.0000000000000438
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Recognizing and treating Mycobacterium avium complex pulmonary disease (MAC-PD)

Zhi Peng Li
JAAPA
Mycobacterium research and diagnosis
article

Recognizing and treating Mycobacterium avium complex pulmonary disease (MAC-PD)

Zhi Peng Li
article en

Abstract

Mycobacterium avium complex pulmonary disease (MAC-PD) is an increasingly recognized cause of chronic pulmonary infection, yet it remains frequently missed in clinical practice due to its nonspecific presentation and overlap with more common conditions. This clinical review summarizes the pathogenesis, risk factors, clinical presentation, diagnostic criteria, differential diagnosis, pharmacologic treatment, and supportive care of MAC-PD for advanced practice clinicians. Two clinical phenotypes are discussed: fibrocavitary disease, seen more often in older men with structural lung disease, and nodular bronchiectatic disease, seen more often in older women. Diagnosis requires meeting clinical, radiographic, and microbiologic criteria per the 2020 ATS/ERS/ESCMID/IDSA guideline. Treatment consists of a macrolide-based three-drug regimen guided by disease phenotype, severity, and drug susceptibility that is continued for at least 12 months after sputum culture conversion. Airway clearance therapy, nutritional support, and mitigation of environmental and other modifiable risk factors are integral to comprehensive management. Recognizing MAC-PD early and initiating appropriate treatment can prevent progressive lung damage and improve quality of life for affected patients.

JAAPAVol. 39(12)
Mycobacterium research and diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon